Shire appoints Sara Mathew to board of directors
pharmafile | September 2, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Sara Mathew, Shire
Shire has appointed Sara Mathew to its board of directors as a non-executive director.
Mathew will also be a member of the audit, compliance and risk committee of the Shire board, and took on the role on September 1.
Mathew previously served as chairman, president and chief executive of business information provider Dun & Bradstreet, from which she retired in December 2013. During her 12 years at D&B, she helped drive the transformation of the company from a data provider to an innovative digital enterprise that leverages big data, insights and analytics. In 2013, Sara was named the top value creator in the S&P 500 by Chief Executive magazine.
Before joining D&B, Mathew spent 18 years at Procter & Gamble in a variety of global senior finance and management positions, including vice president of finance for Australia, Asia and India. She is currently a director of Avon, Campbell Soup and Freddie Mac, and a member of the international advisory council for Zurich Financial Services Group.
Susan Kilsby, Shire’s chair says: “Sara is a highly-skilled global leader who has demonstrated success in driving strategy and transformation to deliver value for stakeholders. She also understands first-hand the power of disruptive technologies to substantially influence business in the future, an emerging dynamic in healthcare. I am confident that her unique combination of skills and experience will further enrich the Shire board of directors as we advance towards becoming a global biotechnology leader.”
Related Content
Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …
Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …
